肺浸润性黏液腺癌治疗进展  

Progress in the treatment of invasive mucinous adenocarcinoma of the lung

作　　者：牛雪梅 慈明伟 连艳芬 Niu Xuemei;Ci Mingwei;Lian Yanfen(Department of Oncology,Weihai Central Hospital Affiliated to Qingdao University,Weihai 264200,China)

机构地区：[1]青岛大学附属威海市中心医院肿瘤科,威海264200

出　　处：《中华结核和呼吸杂志》2025年第3期286-291,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：肺浸润性黏液腺癌(invasive mucinous adenocarcinoma,IMA)属于肺腺癌的一种特殊亚型,其组织学特点是肿瘤内含有丰富的黏液,具有独特的临床病理特征和免疫表型。关于IMA的病因及发病机制缺乏专门的深入研究,一般认为与普通型肺腺癌相同。由于发病率相对较低,目前对IMA的大规模研究较少,本文旨在从现有的研究进展中归纳和总结IMA的治疗方法,包括手术切除、化学治疗、靶向治疗、免疫治疗和新的治疗方法及这些治疗方法相互的联合,并且探讨了这些最新治疗进展对预后的影响。Invasive mucinous adenocarcinoma belongs to a specific subtype of lung adenocarcinoma,The histological characteristics of the tumor are rich in mucus,with unique clinicopathological features and immunophenotype.There is no specific in-depth study on the etiology and pathogenesis of IMA,and it is generally considered to be the same as common lung adenocarcinoma.Due to its relatively low incidence,there are currently few large-scale studies on IMA,The purpose of this study is to explore the therapeutic strategies of IMA patients from the existing research advances,including surgical resection,chemotherapy,targeted therapy,immunotherapy,and novel therapeutic approaches and their combination,and to explore the impact of these recent therapeutic advances on prognosis.

关 键 词：肺浸润性黏液腺癌 化学治疗 免疫表型 免疫治疗 肺腺癌 靶向治疗 病因及发病机制 组织学特点 

分 类 号：R73[医药卫生—肿瘤]